These studies found that the reduction of p53 (a common mutation in cancer cells) results in specialized ribosomes with a lower fidelity (i.e. stop codons are bypassed) and a greater likelihood to initiate translation through internal ribosome entry sequences (IRESs) (Belin et al., 2009; Marcel et al., 2015, 2013). This evidence concerns the gene TP53 and cancer.